Loading...
Loading...
VIVUS, Inc.
VVUS today announced that Express Scripts, among the country's largest
Pharmacy Benefit Managers (PBMs), has added Qsymia™ to its national pharmacy
formularies, allowing for coverage where available by benefit design of the
first new FDA-approved medication commercially available in the U.S. in over a
decade for the treatment of chronic weight management.
Express Scripts provides the formulary design, pharmaceutical contract
management and claims processing for some of the largest payers and employers
in the U.S.
Qsymia has been added as a standard benefit option to Express Scripts'
national formulary in a tier-3 position with a prior authorization. Under the
Express Scripts plan, participating patients will now pay an estimated $50.00
to $60.00 for their co-payment for a monthly prescription of Qsymia,
approximately one-third of the retail price.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in